title: TaqI polymorphism of VDR gene contributes to breast cancer risk.
abstract: Previous studies on the association of Vitamin D receptor (VDR) TaqI gene polymorphism with breast carcinogenesis have yielded inconsistent and inconclusive findings. The current meta-analysis was performed to provide a more precise assessment on the role of VDR TaqI polymorphism in breast cancer risk. 20 eligible case-control studies involving 9,055 cases and 10,516 controls were identified after a comprehensive literature search of the PubMed, Embase, Web of Science, and Wanfang databases. The pooled odds ratio (OR) with corresponding 95% confidence interval (95% CI) was calculated. Stratified analyses by ethnicity and study quality were conducted for further estimation. All statistical analyses were conducted by use of STATA (STATA Corporation, College Station, TX, Version 11.0). The overall ORs showed that the variant t allele and tt genotype were related to an increased risk of breast cancer (OR(t vs. T) = 1.05, 95% CI 1.01-1.10, P(OR) = 0.025; OR(tt vs. TT) = 1.12, 95% CI 1.03-1.23, P(OR) = 0.011; OR(tt vs. Tt + TT) = 1.10, 95% CI 1.01-1.20, P(OR) = 0.023). Stratified analyses of studies in Caucasians and with high-quality further confirmed the results. However, no significant relationship was observed among Asians. This meta-analysis suggests that the VDR TaqI polymorphism confers risk effect on the breast cancer development, particularly in Caucasians.
authors.affiliation: Division of Vascular, Thyroid and Breast Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.
authors.forename: Hua
authors.initials: H
authors.lastname: Wang
authors.forename: Wenjian
authors.initials: W
authors.lastname: Wang
authors.forename: Dongjie
authors.initials: D
authors.lastname: Yang
authors.forename: Shenming
authors.initials: S
authors.lastname: Wang
mesh_terms: D001943:Breast Neoplasms / Q000208:ethnology / Q000235:genetics*; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D017594:Publication Bias; D018167:Receptors, Calcitriol / Q000235:genetics*
chemical_list: D018167:Receptors, Calcitriol
references.citation: Carcinogenesis. 2009 Jul;30(7):1170-80
references.pmid: 19403841
references.citation: World J Gastroenterol. 2012 Apr 14;18(14):1672-9
references.pmid: 22529698
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1708-17
references.pmid: 21693626
references.citation: Bone. 1995 Aug;17(2 Suppl):33S-38S
references.pmid: 8579895
references.citation: Pharmacogenetics. 2004 Apr;14(4):239-45
references.pmid: 15083068
references.citation: Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10529-34
references.pmid: 9724737
references.citation: Asia Pac J Public Health. 2013 Sep;25(5):368-87
references.pmid: 23709491
references.citation: Endocr Relat Cancer. 2006 Dec;13(4):1109-20
references.pmid: 17158757
references.citation: Cancer Detect Prev. 2009;32(5-6):386-94
references.pmid: 19588543
references.citation: Am J Hum Genet. 2005 Nov;77(5):807-23
references.pmid: 16252240
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Int J Dermatol. 2013 Jun;52(6):705-10
references.pmid: 23488577
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: PLoS One. 2013;8(3):e57967
references.pmid: 23554871
references.citation: Minerva Endocrinol. 2013 Jun;38(2):195-201
references.pmid: 23732374
references.citation: Breast Cancer Res. 2008;10(2):R31
references.pmid: 18419802
references.citation: Front Biosci (Schol Ed). 2013 Jan 01;5:247-60
references.pmid: 23277049
references.citation: J Endocrinol. 1997 Sep;154 Suppl:S57-73
references.pmid: 9379138
references.citation: Carcinogenesis. 1999 Nov;20(11):2131-5
references.pmid: 10545416
references.citation: Discov Med. 2011 Apr;11(59):325-35
references.pmid: 21524386
references.citation: Indian J Cancer. 2013 Jan-Mar;50(1):65-70
references.pmid: 23713049
references.citation: Mol Cell Endocrinol. 2001 May 25;177(1-2):145-59
references.pmid: 11377830
references.citation: Cancer Res. 2000 Jan 15;60(2):305-8
references.pmid: 10667581
references.citation: Front Endocrinol (Lausanne). 2012 Apr 23;3:58
references.pmid: 22649423
references.citation: Arch Med Res. 2013 Apr;44(3):235-41
references.pmid: 23506721
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2313-6
references.pmid: 21828234
references.citation: Ann Epidemiol. 2002 Apr;12(3):182-96
references.pmid: 11897176
references.citation: Breast Cancer Res Treat. 2009 Jun;115(3):629-33
references.pmid: 18587672
references.citation: Biometrika. 1950 Dec;37(3-4):256-66
references.pmid: 14801052
references.citation: Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2001 Aug;18(4):286-8
references.pmid: 11484168
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Mutat Res. 2008 Dec 15;648(1-2):65-72
references.pmid: 18977234
references.citation: Cancer Res. 1999 May 15;59(10):2332-4
references.pmid: 10344739
references.citation: J Cell Physiol. 2010 Feb;222(2):336-46
references.pmid: 19885846
references.citation: Dermatoendocrinol. 2012 Apr 1;4(2):146-51
references.pmid: 22928070
references.citation: Breast Cancer Res Treat. 2002 Jul;74(1):1-7
references.pmid: 12150447
references.citation: BMJ. 1998 Feb 7;316(7129):469; author reply 470-1
references.pmid: 9492685
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1003-16
references.pmid: 21378269
references.citation: Clin J Am Soc Nephrol. 2008 Sep;3(5):1548-54
references.pmid: 18550652
references.citation: Exp Mol Pathol. 2009 Aug;87(1):32-5
references.pmid: 19426727
references.citation: Exp Mol Med. 2003 Dec 31;35(6):550-5
references.pmid: 14749534
references.citation: Anticancer Res. 2006 Jul-Aug;26(4A):2637-45
references.pmid: 16886674
references.citation: J Nutr. 1995 Jun;125(6 Suppl):1690S-1694S
references.pmid: 7782928
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Breast Cancer Res. 2007;9(1):R9
references.pmid: 17244366
references.citation: Expert Rev Anticancer Ther. 2012 May;12(5):585-99
references.pmid: 22594894
references.citation: Breast Cancer Res Treat. 2009 Sep;117(2):391-9
references.pmid: 19145484
references.citation: Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1856-67
references.pmid: 22892281
references.citation: Eur J Hum Genet. 2005 Jul;13(7):840-8
references.pmid: 15827565
references.citation: Tohoku J Exp Med. 2011;224(3):201-8
references.pmid: 21701125
references.citation: Am J Epidemiol. 2007 Dec 15;166(12):1409-19
references.pmid: 17934201
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1503-4
references.pmid: 12433736
references.citation: Int J Cancer. 1999 Dec 10;83(6):723-6
references.pmid: 10597185
references.citation: Gene. 2013 Jul 25;524(2):84-9
references.pmid: 23644255
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120